Stoke Therapeutics (STOK) Financials

$9.47 -0.29 (-2.97%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$9.46 -0.01 (-0.11%)

As of 04/28/2025 04:24 PM Eastern

Annual Income Statements for Stoke Therapeutics

This table shows Stoke Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-101	-105	-89
Consolidated Net Income / (Loss)	-101	-105	-89
Net Income / (Loss) Continuing Operations	-101	-105	-89
Total Pre-Tax Income	-101	-105	-89
Total Operating Income	-104	-115	-101
Total Gross Profit	12	8.78	37
Total Revenue	12	8.78	37
Operating Revenue	12	8.78	37
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	117	124	138
Selling, General & Admin Expense	39	41	49
Research & Development Expense	78	82	89
Total Other Income / (Expense), net	3.29	10	12
Interest & Investment Income	3.12	9.91	13
Other Income / (Expense), net	0.17	0.17	-0.25
Basic Earnings per Share	($2.60)	($2.38)	($1.65)
Weighted Average Basic Shares Outstanding	38.90M	43.99M	54.01M
Diluted Earnings per Share	($2.60)	($2.38)	($1.65)
Weighted Average Diluted Shares Outstanding	38.90M	43.99M	54.01M
Weighted Average Basic & Diluted Shares Outstanding	44.15M	46.30M	54.08M

This table shows Stoke Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-26	-25	-23	-30	-24	-27	-26	-26	-26	-11
Consolidated Net Income / (Loss)	-26	-26	-23	-31	-25	-27	-26	-26	-26	-10
Net Income / (Loss) Continuing Operations	-26	-26	-23	-31	-25	-27	-26	-26	-26	-10
Total Pre-Tax Income	-26	-26	-23	-31	-25	-27	-26	-26	-26	-10
Total Operating Income	-27	-27	-25	-33	-27	-30	-28	-29	-30	-14
Total Gross Profit	2.91	3.27	5.15	-2.48	3.31	2.80	4.22	4.83	4.89	23
Total Revenue	2.91	3.27	5.15	-2.48	3.31	2.80	4.22	4.83	4.89	23
Operating Revenue	-	-	5.15	-2.48	3.31	2.80	4.22	4.83	4.89	23
Total Operating Expenses	30	30	30	31	31	32	33	34	35	36
Selling, General & Admin Expense	9.94	9.38	10	10	10	11	10	13	13	13
Research & Development Expense	20	21	20	21	20	22	22	21	22	23
Total Other Income / (Expense), net	1.04	1.52	2.15	2.61	2.69	2.63	2.00	3.65	3.57	3.17
Interest & Investment Income	1.00	1.48	2.10	2.57	2.65	2.59	2.43	3.70	3.55	2.97
Other Income / (Expense), net	0.04	0.04	0.04	0.04	0.04	0.04	-0.43	-0.05	0.03	0.20
Basic Earnings per Share	($0.66)	($0.65)	($0.53)	($0.69)	($0.55)	($0.61)	($0.57)	($0.46)	($0.47)	($0.15)
Weighted Average Basic Shares Outstanding	39.42M	38.90M	42.54M	44.19M	44.27M	43.99M	46.25M	55.77M	56.34M	54.01M
Diluted Earnings per Share	($0.66)	($0.65)	($0.53)	($0.69)	($0.55)	($0.61)	($0.57)	($0.46)	($0.47)	($0.15)
Weighted Average Diluted Shares Outstanding	39.42M	38.90M	42.54M	44.19M	44.27M	43.99M	46.25M	55.77M	56.34M	54.01M
Weighted Average Basic & Diluted Shares Outstanding	39.43M	44.15M	44.19M	44.26M	44.65M	46.30M	52.12M	52.65M	52.97M	54.08M

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-31	78	-63
Net Cash From Operating Activities	-32	-81	-87
Net Cash From Continuing Operating Activities	-32	-81	-87
Net Income / (Loss) Continuing Operations	-101	-105	-89
Consolidated Net Income / (Loss)	-101	-105	-89
Depreciation Expense	1.55	2.47	2.18
Amortization Expense	-0.21	-0.33	-1.64
Non-Cash Adjustments To Reconcile Net Income	25	28	30
Changes in Operating Assets and Liabilities, net	43	-6.03	-28
Net Cash From Investing Activities	-46	106	-107
Net Cash From Continuing Investing Activities	-46	106	-107
Purchase of Property, Plant & Equipment	-3.96	-1.62	-0.20
Purchase of Investments	-201	0.00	-167
Sale and/or Maturity of Investments	159	108	60
Net Cash From Financing Activities	46	53	131
Net Cash From Continuing Financing Activities	46	53	131
Issuance of Common Equity	46	53	9.49
Other Financing Activities, net	0.49	0.37	122

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	46	0.16	77	1.72	-2.08	1.47	-13	15	-43	-22
Net Cash From Operating Activities	-22	-22	-21	-22	-17	-21	-25	-17	-22	-23
Net Cash From Continuing Operating Activities	-22	-22	-21	-22	-17	-21	-25	-17	-22	-23
Net Income / (Loss) Continuing Operations	-26	-26	-23	-31	-25	-27	-26	-26	-26	-10
Consolidated Net Income / (Loss)	-26	-26	-23	-31	-25	-27	-26	-26	-26	-10
Depreciation Expense	0.39	0.61	0.60	0.61	0.64	0.62	0.56	0.55	0.54	0.53
Amortization Expense	-0.10	-0.15	0.03	-0.15	-0.12	-0.09	-0.02	-0.29	-0.55	-0.78
Non-Cash Adjustments To Reconcile Net Income	6.46	6.33	6.44	7.32	7.12	6.65	5.96	7.99	8.07	7.72
Changes in Operating Assets and Liabilities, net	-2.69	-3.51	-5.88	1.07	-0.35	-0.88	-4.69	-0.03	-3.24	-20
Net Cash From Investing Activities	67	22	53	23	15	15	9.99	-88	-30	0.82
Net Cash From Continuing Investing Activities	67	22	53	23	15	15	9.99	-88	-30	0.82
Purchase of Property, Plant & Equipment	-2.03	-0.41	-0.17	-0.84	-0.38	-0.23	-0.01	-0.05	-0.10	-0.04
Purchase of Investments	-9.71	4.87	-	-	-	-	-	-	-50	-29
Sale and/or Maturity of Investments	79	18	53	24	15	15	10	-	20	30
Net Cash From Financing Activities	0.43	0.04	45	0.05	0.56	7.34	1.72	121	8.16	0.57
Net Cash From Continuing Financing Activities	0.43	0.04	45	0.05	0.56	7.34	1.72	121	8.16	0.57
Issuance of Common Equity	46	-	0.15	45	0.35	7.34	1.47	-	8.02	0.00
Other Financing Activities, net	-45	0.04	45	-45	0.21	0.00	0.25	121	0.14	0.57

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	256	228	272
Total Current Assets	244	215	233
Cash & Equivalents	114	191	128
Restricted Cash	-	0.00	0.08
Short-Term Investments	116	9.95	89
Note & Lease Receivable	0.59	0.06	0.70
Prepaid Expenses	11	11	11
Other Current Assets	2.96	2.56	3.97
Plant, Property, & Equipment, net	6.68	5.82	3.91
Total Noncurrent Assets	5.32	7.18	35
Long-Term Investments	-	0.00	30
Other Noncurrent Operating Assets	5.32	7.18	5.07
Total Liabilities & Shareholders' Equity	256	228	272
Total Liabilities	71	69	43
Total Current Liabilities	31	31	40
Accounts Payable	0.77	1.70	2.50
Accrued Expenses	16	14	19
Current Deferred Revenue	15	15	19
Total Noncurrent Liabilities	40	38	2.48
Noncurrent Deferred Revenue	37	33	0.00
Other Noncurrent Operating Liabilities	2.97	4.88	2.48
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	185	160	229
Total Preferred & Common Equity	185	160	229
Total Common Equity	185	160	229
Common Stock	483	561	720
Retained Earnings	-297	-402	-491
Accumulated Other Comprehensive Income / (Loss)	-1.18	-0.02	-0.15

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	278	282	257	240	205	308	293
Total Current Assets	265	270	246	230	193	297	254
Cash & Equivalents	113	190	192	190	179	193	150
Restricted Cash	0.57	-	-	-	-	0.08	0.08
Short-Term Investments	138	63	39	25	0.00	89	89
Note & Lease Receivable	0.40	0.49	0.14	0.10	0.01	0.31	0.69
Prepaid Expenses	13	10	11	11	11	10	9.84
Other Current Assets	0.00	5.88	3.70	4.27	3.96	4.29	3.81
Plant, Property, & Equipment, net	7.16	6.79	6.47	6.22	5.28	4.77	4.33
Total Noncurrent Assets	5.30	4.77	4.22	3.65	6.63	5.99	35
Long-Term Investments	-	-	-	-	-	-	30
Other Noncurrent Operating Assets	5.30	4.77	4.22	3.65	6.63	5.99	5.42
Total Liabilities & Shareholders' Equity	278	282	257	240	205	308	293
Total Liabilities	73	68	67	67	65	65	61
Total Current Liabilities	29	32	22	25	36	44	50
Accounts Payable	1.91	4.30	1.56	3.08	2.10	3.95	2.49
Accrued Expenses	14	14	12	13	13	15	16
Current Deferred Revenue	13	13	8.06	8.74	21	26	32
Total Noncurrent Liabilities	45	36	45	42	29	21	11
Noncurrent Deferred Revenue	41	34	43	41	25	17	8.29
Other Noncurrent Operating Liabilities	3.61	2.30	1.63	0.96	4.21	3.61	3.05
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	204	214	190	173	140	243	232
Total Preferred & Common Equity	204	214	190	173	140	243	232
Total Common Equity	204	214	190	173	140	243	232
Common Stock	477	534	541	548	569	697	712
Retained Earnings	-271	-320	-350	-375	-428	-454	-480
Accumulated Other Comprehensive Income / (Loss)	-1.70	-0.60	-0.38	-0.15	0.00	-0.02	0.17

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	-29.22%	316.34%
EBITDA Growth	-21.28%	-9.34%	10.12%
EBIT Growth	-21.26%	-10.00%	11.33%
NOPAT Growth	-21.25%	-9.98%	11.68%
Net Income Growth	-17.79%	-3.59%	15.01%
EPS Growth	-11.11%	8.46%	30.67%
Operating Cash Flow Growth	52.37%	-154.40%	-7.13%
Free Cash Flow Firm Growth	48.97%	-174.45%	-14.12%
Invested Capital Growth	-2,100.98%	6.52%	57.50%
Revenue Q/Q Growth	35.78%	-5.06%	118.34%
EBITDA Q/Q Growth	-2.47%	-2.12%	13.15%
EBIT Q/Q Growth	-2.61%	-2.15%	13.67%
NOPAT Q/Q Growth	-2.60%	-2.15%	13.58%
Net Income Q/Q Growth	-1.21%	-1.26%	15.62%
EPS Q/Q Growth	1.14%	1.65%	21.80%
Operating Cash Flow Q/Q Growth	-23.75%	2.08%	-3.02%
Free Cash Flow Firm Q/Q Growth	-38.50%	2.07%	-9.57%
Invested Capital Q/Q Growth	6.94%	-0.26%	52.10%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-829.13%	-1,280.90%	-276.53%
Operating Margin	-841.24%	-1,307.21%	-277.31%
EBIT Margin	-839.90%	-1,305.32%	-277.99%
Profit (Net Income) Margin	-814.73%	-1,192.47%	-243.42%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	97.00%	91.35%	87.56%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-50.20%	-60.80%	-45.80%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-42.10%	-47.32%	-40.66%
Return on Assets (ROA)	-40.84%	-43.23%	-35.60%
Return on Common Equity (ROCE)	-50.20%	-60.80%	-45.80%
Return on Equity Simple (ROE_SIMPLE)	-54.68%	-65.62%	-38.85%
Net Operating Profit after Tax (NOPAT)	-73	-80	-71
NOPAT Margin	-588.87%	-915.05%	-194.12%
Net Nonoperating Expense Percent (NNEP)	-12.47%	-11.30%	-8.04%
Return On Investment Capital (ROIC_SIMPLE)	-	-50.35%	-30.98%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	313.78%	470.64%	133.48%
R&D to Revenue	627.46%	936.57%	243.83%
Operating Expenses to Revenue	941.24%	1,407.21%	377.31%
Earnings before Interest and Taxes (EBIT)	-104	-115	-102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-103	-112	-101
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.97	1.47	2.55
Price to Tangible Book Value (P/TBV)	1.97	1.47	2.55
Price to Revenue (P/Rev)	29.34	26.75	15.98
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	10.83	3.81	9.23
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.12	-1.25	-1.15
Leverage Ratio	1.23	1.41	1.29
Compound Leverage Factor	1.19	1.28	1.13
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	1.14	-1.06	5.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.77	6.99	5.81
Quick Ratio	7.33	6.54	5.43
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-30	-83	-95
Operating Cash Flow to CapEx	-804.29%	-5,016.52%	-42,783.74%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.05	0.04	0.15
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	2.29	1.41	7.51
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-45	-42	-18
Invested Capital Turnover	-0.53	-0.20	-1.23
Increase / (Decrease) in Invested Capital	-43	2.92	24
Enterprise Value (EV)	134	33	337
Market Capitalization	364	235	584
Book Value per Share	$4.69	$3.57	$4.32
Tangible Book Value per Share	$4.69	$3.57	$4.32
Total Capital	185	160	229
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-230	-201	-247
Capital Expenditures (CapEx)	3.96	1.62	0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-17	-17	-24
Debt-free Net Working Capital (DFNWC)	213	185	193
Net Working Capital (NWC)	213	185	193
Net Nonoperating Expense (NNE)	28	24	18
Net Nonoperating Obligations (NNO)	-230	-201	-247
Total Depreciation and Amortization (D&A)	1.34	2.14	0.54
Debt-free, Cash-free Net Working Capital to Revenue	-136.39%	-192.19%	-66.40%
Debt-free Net Working Capital to Revenue	1,714.44%	2,101.59%	527.15%
Net Working Capital to Revenue	1,714.44%	2,101.59%	527.15%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.60)	($2.38)	($1.65)
Adjusted Weighted Average Basic Shares Outstanding	38.90M	43.99M	54.01M
Adjusted Diluted Earnings per Share	($2.60)	($2.38)	($1.65)
Adjusted Weighted Average Diluted Shares Outstanding	38.90M	43.99M	54.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.15M	46.30M	54.08M
Normalized Net Operating Profit after Tax (NOPAT)	-73	-80	-71
Normalized NOPAT Margin	-588.87%	-915.05%	-194.12%
Pre Tax Income Margin	-814.73%	-1,192.47%	-243.42%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	71.73%	-176.79%	13.87%	-14.32%	-18.17%	294.72%	47.94%	707.35%
EBITDA Growth	-20.06%	-10.27%	1.04%	-30.57%	0.53%	-8.75%	-17.66%	11.07%	-12.38%	52.74%
EBIT Growth	-19.72%	-10.82%	0.42%	-31.85%	-0.32%	-8.89%	-16.85%	11.53%	-10.23%	54.46%
NOPAT Growth	-19.68%	-10.80%	0.42%	-31.79%	-0.32%	-8.88%	-14.91%	11.79%	-10.17%	53.85%
Net Income Growth	-15.55%	-4.94%	8.54%	-24.35%	6.01%	-5.08%	-16.98%	16.18%	-7.69%	61.12%
EPS Growth	-10.00%	4.41%	19.70%	-9.52%	16.67%	6.15%	-7.55%	33.33%	14.55%	75.41%
Operating Cash Flow Growth	-50.22%	-37.61%	-165.73%	-9.39%	21.74%	7.71%	-15.03%	19.83%	-25.22%	-12.32%
Free Cash Flow Firm Growth	289.13%	244.76%	-175.38%	-189.45%	-183.95%	-199.74%	29.99%	33.81%	-0.71%	-42.25%
Invested Capital Growth	-4,073.64%	-2,100.98%	25.15%	20.48%	13.23%	6.52%	4.05%	4.62%	11.04%	57.50%
Revenue Q/Q Growth	-10.09%	12.53%	57.60%	-148.16%	233.33%	-15.33%	50.52%	14.59%	1.30%	362.08%
EBITDA Q/Q Growth	-6.91%	0.54%	9.96%	-36.38%	18.56%	-8.74%	2.58%	-3.08%	-2.92%	54.27%
EBIT Q/Q Growth	-7.58%	-0.10%	9.16%	-34.78%	18.15%	-8.65%	2.52%	-2.05%	-1.99%	55.12%
NOPAT Q/Q Growth	-7.57%	-0.10%	9.14%	-34.72%	18.12%	-8.64%	4.11%	-3.42%	-2.25%	54.49%
Net Income Q/Q Growth	-5.92%	1.75%	12.12%	-35.97%	19.94%	-9.84%	2.17%	2.57%	-2.86%	60.34%
EPS Q/Q Growth	-4.76%	1.52%	18.46%	-30.19%	20.29%	-10.91%	6.56%	19.30%	-2.17%	68.09%
Operating Cash Flow Q/Q Growth	-10.68%	-1.44%	4.55%	-2.08%	20.82%	-19.62%	-18.97%	28.86%	-23.68%	-7.30%
Free Cash Flow Firm Q/Q Growth	-20.10%	-21.78%	-229.47%	-10.56%	25.02%	7.07%	9.12%	-4.52%	-14.10%	-31.25%
Invested Capital Q/Q Growth	7.32%	6.94%	10.94%	-3.52%	-1.13%	-0.26%	8.58%	-2.90%	5.68%	52.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-923.24%	-816.03%	-466.21%	0.00%	-806.47%	-1,035.70%	-670.33%	-603.00%	-612.63%	-60.63%
Operating Margin	-934.53%	-831.29%	-479.23%	0.00%	-823.28%	-1,056.30%	-672.96%	-607.37%	-613.06%	-60.38%
EBIT Margin	-933.08%	-830.04%	-478.42%	0.00%	-822.04%	-1,054.80%	-683.11%	-608.36%	-612.48%	-59.49%
Profit (Net Income) Margin	-898.83%	-784.80%	-437.60%	0.00%	-741.90%	-962.44%	-625.57%	-531.88%	-540.05%	-46.35%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.33%	94.55%	91.47%	92.27%	90.25%	91.24%	91.58%	87.43%	88.17%	77.91%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-45.22%	-50.20%	-43.62%	-50.64%	-54.83%	-60.80%	-61.29%	-47.85%	-52.06%	-45.80%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-32.08%	-41.61%	-23.30%	0.00%	-29.38%	-38.24%	-22.01%	-32.66%	-38.46%	-8.70%
Return on Assets (ROA)	-30.91%	-39.34%	-21.31%	0.00%	-26.52%	-34.89%	-20.15%	-28.55%	-33.91%	-6.78%
Return on Common Equity (ROCE)	-45.22%	-50.20%	-43.62%	-50.64%	-54.83%	-60.80%	-61.29%	-47.85%	-52.06%	-45.80%
Return on Equity Simple (ROE_SIMPLE)	-48.92%	0.00%	-46.28%	-55.19%	-59.77%	0.00%	-77.33%	-42.67%	-45.43%	0.00%
Net Operating Profit after Tax (NOPAT)	-19	-19	-17	-23	-19	-21	-20	-21	-21	-9.56
NOPAT Margin	-654.17%	-581.91%	-335.46%	0.00%	-576.29%	-739.41%	-471.07%	-425.16%	-429.14%	-42.27%
Net Nonoperating Expense Percent (NNEP)	-2.91%	-2.95%	-1.92%	-2.90%	-2.35%	-2.90%	-3.01%	-2.01%	-2.24%	-0.41%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-12.98%	-	-	-	-4.17%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	342.31%	287.03%	198.19%	0.00%	310.49%	378.79%	242.41%	269.86%	259.34%	56.80%
R&D to Revenue	692.22%	644.26%	381.04%	0.00%	612.79%	777.51%	530.55%	437.51%	453.72%	103.58%
Operating Expenses to Revenue	1,034.53%	931.29%	579.23%	0.00%	923.28%	1,156.30%	772.96%	707.37%	713.06%	160.38%
Earnings before Interest and Taxes (EBIT)	-27	-27	-25	-33	-27	-30	-29	-29	-30	-13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-27	-24	-33	-27	-29	-28	-29	-30	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.48	1.97	1.72	2.47	1.01	1.47	4.45	2.90	2.79	2.55
Price to Tangible Book Value (P/TBV)	2.48	1.97	1.72	2.47	1.01	1.47	4.45	2.90	2.79	2.55
Price to Revenue (P/Rev)	55.40	29.34	25.26	53.11	18.86	26.75	79.69	46.46	38.65	15.98
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	27.79	10.83	7.84	26.94	0.00	3.81	56.93	27.85	22.57	9.23
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.11	-1.12	-1.21	-1.22	-1.24	-1.25	-1.22	-1.19	-1.19	-1.15
Leverage Ratio	1.20	1.23	1.32	1.35	1.37	1.41	1.38	1.30	1.32	1.29
Compound Leverage Factor	1.16	1.16	1.20	1.24	1.24	1.28	1.26	1.14	1.16	1.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	3.49	2.14	2.44	2.97	0.07	0.17	3.36	5.15	4.60	6.53
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.19	7.77	8.57	11.28	9.13	6.99	5.43	6.67	5.09	5.81
Quick Ratio	8.75	7.33	8.06	10.61	8.52	6.54	5.02	6.34	4.81	5.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	30	24	-31	-34	-25	-24	-21	-22	-26	-34
Operating Cash Flow to CapEx	-1,086.50%	-5,470.17%	-12,943.03%	-2,598.33%	-4,507.05%	-9,017.03%	-204,716.67%	-37,993.48%	-20,985.44%	-55,221.43%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.03	0.05	0.05	0.03	0.04	0.04	0.03	0.05	0.06	0.15
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.81	2.29	2.46	1.43	1.38	1.41	1.30	2.70	3.17	7.51
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-48	-45	-40	-41	-42	-42	-38	-39	-37	-18
Invested Capital Turnover	-0.39	-0.53	-0.31	-0.19	-0.21	-0.20	-0.20	-0.38	-0.42	-1.23
Increase / (Decrease) in Invested Capital	-49	-43	13	11	6.36	2.92	1.61	1.90	4.61	24
Enterprise Value (EV)	254	134	114	238	-40	33	447	422	378	337
Market Capitalization	506	364	368	470	174	235	625	704	647	584
Book Value per Share	$5.18	$4.69	$4.84	$4.30	$3.91	$3.57	$3.03	$4.66	$4.41	$4.32
Tangible Book Value per Share	$5.18	$4.69	$4.84	$4.30	$3.91	$3.57	$3.03	$4.66	$4.41	$4.32
Total Capital	204	185	214	190	173	160	140	243	232	229
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-252	-230	-254	-231	-215	-201	-179	-282	-269	-247
Capital Expenditures (CapEx)	2.03	0.41	0.17	0.84	0.38	0.23	0.01	0.05	0.10	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-16	-17	-15	-7.05	-9.90	-17	-21	-30	-36	-24
Debt-free Net Working Capital (DFNWC)	236	213	239	224	205	185	158	252	204	193
Net Working Capital (NWC)	236	213	239	224	205	185	158	252	204	193
Net Nonoperating Expense (NNE)	7.11	6.63	5.26	7.37	5.48	6.25	6.51	5.16	5.43	0.92
Net Nonoperating Obligations (NNO)	-252	-230	-254	-231	-215	-201	-179	-282	-269	-247
Total Depreciation and Amortization (D&A)	0.29	0.46	0.63	0.47	0.52	0.54	0.54	0.26	-0.01	-0.26
Debt-free, Cash-free Net Working Capital to Revenue	-179.71%	-136.39%	-102.80%	-79.73%	-107.05%	-192.19%	-266.39%	-195.03%	-212.21%	-66.40%
Debt-free Net Working Capital to Revenue	2,581.06%	1,714.44%	1,639.82%	2,536.97%	2,214.73%	2,101.59%	2,010.26%	1,665.99%	1,216.98%	527.15%
Net Working Capital to Revenue	2,581.06%	1,714.44%	1,639.82%	2,536.97%	2,214.73%	2,101.59%	2,010.26%	1,665.99%	1,216.98%	527.15%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.66)	($0.65)	($0.53)	($0.69)	($0.55)	($0.61)	($0.57)	($0.46)	($0.47)	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	39.42M	38.90M	42.54M	44.19M	44.27M	43.99M	46.25M	55.77M	56.34M	54.01M
Adjusted Diluted Earnings per Share	($0.63)	($0.65)	($0.53)	($0.69)	($0.55)	($0.61)	($0.57)	($0.46)	($0.47)	($0.15)
Adjusted Weighted Average Diluted Shares Outstanding	39.26M	38.90M	42.54M	44.19M	44.27M	43.99M	46.25M	55.77M	56.34M	54.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.43M	44.15M	44.19M	44.26M	44.65M	46.30M	52.12M	52.65M	52.97M	54.08M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-19	-17	-23	-19	-21	-20	-21	-21	-9.56
Normalized NOPAT Margin	-654.17%	-581.91%	-335.46%	0.00%	-576.29%	-739.41%	-471.07%	-425.16%	-429.14%	-42.27%
Pre Tax Income Margin	-898.83%	-784.80%	-437.60%	0.00%	-741.90%	-962.44%	-625.57%	-531.88%	-540.05%	-46.35%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Stoke Therapeutics' Financials

When does Stoke Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Stoke Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Stoke Therapeutics' net income changed over the last 2 years?

Stoke Therapeutics' net income appears to be on a downward trend, with a most recent value of -$88.98 million in 2024, falling from -$101.07 million in 2022. The previous period was -$104.70 million in 2023.

What is Stoke Therapeutics's operating income?

Stoke Therapeutics's total operating income in 2024 was -$101.37 million, based on the following breakdown:

Total Gross Profit: $36.56 million
Total Operating Expenses: $137.93 million

How has Stoke Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Stoke Therapeutics' total revenue changed from $12.41 million in 2022 to $36.56 million in 2024, a change of 194.7%.

How much debt does Stoke Therapeutics have?

Stoke Therapeutics' total liabilities were at $42.53 million at the end of 2024, a 38.2% decrease from 2023, and a 40.3% decrease since 2022.

How much cash does Stoke Therapeutics have?

In the past 2 years, Stoke Therapeutics' cash and equivalents has ranged from $113.56 million in 2022 to $191.44 million in 2023, and is currently $127.98 million as of their latest financial filing in 2024.

How has Stoke Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Stoke Therapeutics' book value per share changed from 4.69 in 2022 to 4.32 in 2024, a change of -7.8%.

Related Companies

This page (NASDAQ:STOK) was last updated on 4/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Financials

Frequently Asked Questions About Stoke Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Financials

Annual Income Statements for Stoke Therapeutics

Quarterly Income Statements for Stoke Therapeutics

Annual Cash Flow Statements for Stoke Therapeutics

Quarterly Cash Flow Statements for Stoke Therapeutics

Annual Balance Sheets for Stoke Therapeutics

Quarterly Balance Sheets for Stoke Therapeutics

Annual Metrics and Ratios for Stoke Therapeutics

Quarterly Metrics and Ratios for Stoke Therapeutics

Frequently Asked Questions About Stoke Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools